A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Adalimumab (Primary) ; Apremilast (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Leflunomide (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Prednisolone (Primary) ; Secukinumab (Primary) ; Sulfasalazine (Primary) ; Tofacitinib (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms ATTRACTOR
- 29 Oct 2021 Status changed from not yet recruiting to recruiting.
- 12 May 2021 New source identified and integrated European Clinical Trials Database (EudraCT2020-001899-14).
- 03 Nov 2020 New trial record